Latest news with #GLP-1
Business Insider
4 hours ago
- Business
- Business Insider
Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On
Eli Lilly & Co. (LLY) has emerged as one of the most compelling opportunities in the market today. The company is entering the prime of its new chapter, focused on leading the way in weight loss and diabetes treatments. I recently sold my Novo Nordisk (NVO) shares—not because I doubt Novo's science, but because I believe Lilly boasts stronger management, superior operational execution, and greater upside potential over the next one to three years. My 12-month price target for Lilly is $1,100. Confident Investing Starts Here: GLP-1 Leadership with Clinical Momentum Lilly's recent breakthrough has been nothing short of transformational. Its dual GLP-1 therapy, tirzepatide—marketed as Mounjaro for diabetes and Zepbound for obesity—is dominating the market, generating $3.84 billion and $2.31 billion in Q1 FY2025 revenues, respectively. Even more impressive, tirzepatide has shown superior weight loss results compared to Novo Nordisk's semaglutide (Ozempic, Wegovy), with Zepbound users achieving around 20% weight loss versus roughly 14% in Wegovy studies. The data is clear, and momentum is firmly on Lilly's side. Adding to my confidence is the strength of Lilly's product pipeline. Orforglipron, an oral GLP-1 candidate, recently delivered compelling Phase 3 results as the first oral, non-peptide GLP-1 agonist to match the efficacy of injectable therapies—potentially revolutionizing the patient experience in weight-loss treatment. Meanwhile, retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors, achieved a remarkable 24% weight loss in early obesity trials and is advancing rapidly through Phase 3. If these next-generation drugs succeed, they could unlock hundreds of billions in new market value. Management & Manufacturing Excellence Compound Returns Great companies aren't built on strong drugs alone—they're built on strong management. What stands out most about Eli Lilly isn't just its innovative pipeline but the exceptional execution behind it. CEO David Ricks and his team have shown remarkable conviction in targeting diabetes and obesity as key growth drivers, backing that vision with massive investment. Since 2020, Lilly has poured over $50 billion into expanding U.S. manufacturing mega-sites capable of producing injectables and oral medications at scale. This is not only a bet on growth but a strategic move to reduce future risks. With Novo Nordisk facing supply constraints, Lilly's vertical integration of manufacturing infrastructure is a smart play to avoid similar pitfalls. That kind of foresight is exactly what I want managing my investments. Lilly's performance backs this up— Q1 Fiscal 2025 showed gross margins at a stellar 83.5%, up year-over-year. While R&D spending grew, it didn't outpace revenue, creating operating leverage. Selling and administrative costs rose 26%, but top-line revenue jumped 45%, signaling intelligent growth. With a forward P/E near 35 and a sales multiple around 11, Lilly isn't cheap, but it doesn't need to be. Earnings are projected to surge nearly 40% in Fiscal 2026, justifying the valuation. In my view, the market still undervalues Lilly's resilience and staying power. Technical Positioning & Price Outlook After peaking near $955 last year, Lilly shares have pulled back to around $720. On May 14, the stock's relative strength index hit 35, signaling strong value by most technical measures. For retail investors like me, that's a clear opportunity alert. While the stock remains below both its 50-day and 200-day moving averages after a 'Death Cross' indicating short-term bearish momentum, I consider that noise irrelevant for medium- to long-term investors. I view this as a rare chance to buy into a powerhouse at a discount. Given the current earnings growth trajectory, I believe shares will not only revisit but likely surpass their all-time highs soon. My 12-month price target of $1,100 implies roughly 50% upside. Fundamentally, the market is still coming to grips with the massive potential of the GLP-1 market, and I see few obstacles standing in the way of sustained growth. Is Eli Lilly a Buy, Sell, or Hold? On Wall Street, Eli Lilly has a consensus Strong Buy rating with 16 Buys, one Hold, and one Sell rating. LLY's average stock price target is $1,003.14, indicating almost 40% upside potential in the next 12 months. That's slightly below my own more bullish estimate, but still remarkable nonetheless. Healthcare Powerhouse Poised for Long-Term Growth Eli Lilly is a completely different company than it was just two or three years ago—now an innovation-driven, operationally disciplined giant leading the biggest secular growth story in healthcare. This isn't a quick trade for me; it's a long-term hold as Lilly scales its GLP-1 pipeline with promising new launches like orforglipron and retatrutide. With management's vision, strong clinical execution, disciplined approach, and significant valuation upside, LLY stands out as one of the most compelling stocks on the market. I've confidently taken my position and am ready to hold steady through the next few years of growth.
Yahoo
5 hours ago
- Business
- Yahoo
BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end. A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug candidate. BGE-102, an internally discovered compound, is distinguished by its novel binding site, high potency, and brain penetration. In preclinical obesity models, BGE-102 delivered dose-dependent weight loss comparable to leading GLP-1 agonist semaglutide, achieving up to 15% reduction as monotherapy and over 20% when combined with semaglutide. The drug also improved insulin sensitivity and demonstrated a robust safety margin in toxicology studies. BioAge Labs, Inc. (NASDAQ:BIOA)'s CEO, Kristen Fortney, Ph.D., highlighted BGE-102's potential as a once-daily oral therapy, either alone or with GLP-1 receptor agonists, by targeting the NLRP3 inflammasome, a key driver of inflammation and metabolic dysfunction in obesity. Pending IND clearance, BioAge Labs, Inc. (NASDAQ:BIOA) will launch Phase 1 trials, with a Phase 1b proof-of-concept study in obesity planned for late 2026. While we acknowledge the potential of BIOA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIOA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indian Express
6 hours ago
- Entertainment
- Indian Express
Karan Johar, Ram Kapoor, Kusha Kapila face Ozempic barbs: Why this appetite for hate when it comes to celebs and their bodies?
Over the past couple of months, there has been a huge amount of column space, air time, and screen time (mostly on reels and recorded podcasts) dedicated to discussing the changing appearances of celebrities. The discussions often bring up the use of weight loss drugs like Ozempic, and the comments under social media posts are shockingly vicious and accusatory. Most recently, there was an online surge of hate towards Bhumi Pednekar after the series Royals started streaming on Netflix. The vile remarks about her lips, her figure and more, indicate that the line between critiquing an actor's performance and body-shaming them has blurred completely. Bhumi is not alone, though. Karan Johar's 'drastic' transformation sent netizens into a frenzy recently. His weight loss triggered a 'the nation wants to know' online, where people casually accused him of using weight loss drugs and then proceeded to offer their opinions on how the Dharma head honcho looked post his weight loss. A post shared by Bhumi Pednekar (@bhumipednekar) Given the huge amount of 'concern' that people showed about the numbers on Karan's weighing scale, the producer-director proceeded to give a bunch of interviews and even shared his diet and workout plan to assure people that he wasn't using medicines to lose weight. Why he needed to explain himself to a bunch of strangers is a question we don't seem to be asking. A post shared by Karan Johar (@karanjohar) Karan was preceded by actor Ram Kapoor, who lost not just 55 kgs but presumably any future projects with Ekta Kapoor. Ram's transformed appearance triggered an online spat between his wife Gautami Kapoor and Ekta about whether bade or chote ache lagte hain. The less said, the better about these innuendo-laden barbs they threw at each other on Instagram. Like Karan, Ram also proceeded to give interviews and attend podcasts where he repeatedly clarified that he had not used Ozempic or GLP-1 drugs to create his new look. Digital content creator and actor Kusha Kapila has been trolled and questioned about her weight loss. Responding to one such netizen, who asked her about using Ozempic, Kusha had said, 'HI! Will you please specify how you think it's Ozempic? What is your source? Please be honest, and it's nothing to be ashamed of.' When the person said she didn't have an answer, Kusha added, 'Acha so it's totally assumption. Cool. So, without shame and full honesty, it's not Ozempic. It's consistent workout and clean eating. Hope that answers your question.' A post shared by Ram Kapoor (@iamramkapoor) Ironically, the trolls are just as vicious and nasty when a celebrity gains weight or shows signs of ageing. Take Aishwarya Rai Bachchan, for example. Once hailed as the most beautiful woman on the planet, the actor and former Miss World has been the victim of online bullying about her weight, her clothes, her hairstyle and even the colour of her lipstick. There seems to be a Goldilocks-like standard of perfection for celebrities, that allows them to keep projecting their inadequacy and self-loathing onto them. Audiences often build a perception or attach certain attributes to public figures that help to form a connection with them. Bhumi, for example, thrives in roles which are powerful and yet woman next door. She has proven her talent in films like Bhakshak, Bheed, Lust Stories, Badhai Do and of course her memorable debut film Dum Laga Ke Haisha. Over the past few years, the actor has transformed herself considerably, and the creation of a glamorous new avatar has coincided with films like Thank You For Coming, The Lady Killer, Mere Husband Ki Biwi, and now Royals, which haven't been her best performances on screen. It seems like the disconnect with her characters on screen, or couture choices off screen, has translated to body shaming and trolling. Ram Kapoor, who gained nationwide fame playing the cherubic but lovable Mr. Kapoor on the television show Bade Ache Lagte Hain, has always had a great screen presence and charm. But when he lost a huge amount of weight, fans felt like he had lost the imperfect, everyman essence that made him popular. Karan has unfortunately become the favourite punching bag for trolls, especially since the pandemic. No matter what he does or doesn't do, the online savages are always baying for his blood. While these may be possible explanations, they do not and cannot justify personal attacks or casting aspersions on any individual. There may be several reasons why a celebrity, like every one of us, undergoes a physical transformation; whether that's weight loss, weight gain, or surgical modifications to their appearance. Maybe it's their health, maybe it's the pressure of working in an industry that, inspite of all its talk on body positivity, seems to be doubling down on setting impossible beauty standards for stars. Social media and zooming into pictures of celebrities has only added to the pressure of looking perfect constantly. Think about it, when was the last time you saw a plus-sized leading man or leading lady in any mainstream film? In fact, there has never been a more homogenous-looking bunch of stars at public events and award shows. The sad truth is that we love talking about how a person looks. Most conversations or small talk start with comments about whether a person has gained or lost weight, or changed physically in any way. All of us dread meeting that one friend or relative who doesn't hesitate to make cruel comments with the disclaimer of 'concern', added. We seem to live in a toxic society where we are comfortable as long as we feel the other person is not good enough or does not feel good about themselves like we do. This impulse is only magnified a hundredfold when there is a celebrity involved. While changing the mindset of a million people online may be difficult, celebrities can shift the discussion from their bodies to their body of work by not using their weight or weight loss as a PR peg. More importantly, don't discuss personalised diet plans and exercise plans on public platforms because no matter how many disclaimers are added, there is always the risk of people blindly following someone else's food or exercise regimen. There is nothing more fickle than one's physical appearance. Ageing is a privilege, and our weight often reflects a lot more than our eating habits. If only there were a drug that could suppress our appetite for spewing hate on others. We could call it Mind Your Own Business 101 or MYOB 101.
Yahoo
12 hours ago
- Business
- Yahoo
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago. Lilly will also host an investor event to highlight the company's cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions. The event will be held on Sunday, June 22 at 6:30 p.m. CDT and will be accessible via a live webcast on the "Webcasts & Presentations" section of Lilly's investor website. A replay will be available on the website following the event. Presentation HighlightsOrforglipron (investigational small molecule GLP-1 receptor agonist):In an ADA-sponsored symposium, Lilly will share results from the ACHIEVE-1 Phase 3 trial, which evaluated the safety and efficacy of orforglipron in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Insulin efsitora alfa (investigational once-weekly basal insulin):In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated once-weekly efsitora in adults with type 2 diabetes. Bimagrumab (investigational activin pathway inhibitor):In a third ADA-sponsored symposium, Lilly will share results from the BELIEVE Phase 2b trial, which evaluated bimagrumab alone and in combination with semaglutide in adults with overweight or obesity without type 2 diabetes. A selection of abstract titles and presentation details are listed below: Orforglipron (investigational small molecule GLP-1 receptor agonist):Presentation Title: Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?Presentation Date & Time: Saturday, June 21, 8 to 9:30 a.m. CDT Location: W375 APresenter: Julio Rosenstock, MD Insulin efsitora alfa (investigational once-weekly basal insulin):Presentation Title: Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!Presentation Date & Time: Sunday, June 22, 1:30 to 3 p.m. CDTLocation: W375 APresenter: Julio Rosenstock, MD; Richard M. Bergenstal, MD; Athena Philis-Tsimikas, MD; Thomas Blevins, MD; Chantal Mathieu, MD, PhD Tirzepatide (Zepbound and Mounjaro):Presentation Title: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 WeeksAbstract Number: 103-ORPresentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDTLocation: W185 A-DPresenter: Dr. Hiddo L. Heerspink, PhD Presentation Title: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)Abstract Number: 144-ORPresentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDTLocation: W196 BCPresenter: Jamy D. Ard, MD Presentation Title: SURMOUNT-5 Tirzepatide vs. Semaglutide for Obesity—Rapid Responders and Associated Weight Reduction and SafetyAbstract Number: 224-ORPresentation Date & Time: Saturday, June 21, 4:30 to 6 p.m. CDTLocation: W181 A-CPresenter: Louis Aronne, MD, FACP, DABOM Presentation Title: Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH TrialAbstract Number: 226-ORPresentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDTLocation: W181 A-CPresenter: Anita Kwan, MSc Presentation Title: Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical TrialAbstract Number: 227-ORPresentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDTLocation: W181 A-CPresenter: Kristina Boye, PhD Retatrutide (investigational GIP/GLP-1/glucagon receptor agonist):Presentation Title: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of ObesityAbstract Number: 2169-LBPresentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDTLocation: Poster Hall (Hall F1)Presenter: Ansarullah, PhD Eloralintide (investigational amylin receptor agonist):Presentation Title: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with CagrilintideAbstract Number: 849-PPresentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDTLocation: Poster Hall (Hall F1)Presenter: Daniel A Briere Presentation Title: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of ConceptAbstract Number: 882-PPresentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDTLocation: Poster Hall (Hall F1)Presenter: Edward J. Pratt, MD Bimagrumab (investigational activin pathway inhibitor):Presentation Title: Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + SemaglutidePresentation Date & Time: Monday, June 23, 8 to 9:30 a.m. CDTLocation: W375 APresenters: Lee M. Kaplan, MD, PhD; Ronenn Roubenoff, MD, MHS; Penelope Montgomery, MD; Steven B. Heymsfield, MD; Louis J. Aronne, MD, FACP, DABOM; Ania M. Jastreboff, MD, PhD About orforglipron Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published preclinical pharmacology data for this molecule together. Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity. About insulin efsitora alfa Insulin efsitora alfa (efsitora) is an investigational once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in Phase 3 development for adults with type 1 and 2 diabetes. About retatrutideRetatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and type 2 diabetes, as well as across multiple obesity-related complications, such as osteoarthritis and obstructive sleep apnea. About eloralintideEloralintide is an investigational selective, long-acting amylin receptor agonist designed to mimic the effects of native amylin while potentially improving tolerability and quality of weight loss. Lilly is studying eloralintide in clinical trials to evaluate its potential efficacy and safety in obesity. About bimagrumabBimagrumab is an investigational monoclonal antibody that blocks activin type II receptors, which may promote muscle growth and fat mass reduction. Bimagrumab was discovered by Novartis and later advanced by Versanis Bio for the treatment of obesity. Versanis Bio was acquired by Lilly in 2023. Lilly is currently running studies of bimagrumab in combination with incretins to assess its ability to improve the quality of weight loss by preserving lean mass while reducing fat mass in adults with overweight or obesity. About tirzepatide Tirzepatide is a once-weekly dual GIP receptor and GLP-1 receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and morbidity/mortality in obesity (MMO) are ongoing. Tirzepatide has been approved by the U.S. FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control, and as Zepbound for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide is also approved as Mounjaro in some countries outside the U.S. for adults with type 2 diabetes, obesity or those who are overweight who also have a weight-related comorbid condition. Both Mounjaro and Zepbound should be used in combination with diet and exercise. INDICATIONS AND SAFETY SUMMARY WITH WARNINGS Zepbound (ZEHP-bownd) is an injectable prescription medicine that may help adults with: obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider. Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. Zepbound may cause serious side effects, including: Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away. Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools. Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back. Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat. Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery. Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound. Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you. Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures. Common side effects The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away. Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or Before using Zepbound Your healthcare provider should show you how to use Zepbound before you use it for the first time. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider: ❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food? ❑ Do you take diabetes medicines, such as insulin or sulfonylureas? ❑ Do you have a history of diabetic retinopathy? ❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)? ❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements? ❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). How to take Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222. Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial. Learn more Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you. ZP CON BS 20DEC2024 Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. INDICATION AND SAFETY SUMMARY WITH WARNINGS Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. Warnings - Mounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider. Do not use Mounjaro if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Mounjaro if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Mounjaro if you are allergic to it or any of the ingredients in Mounjaro. Mounjaro may cause serious side effects, including: Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back. Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery. Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat. Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration. Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away. Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro. Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools. Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Mounjaro may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Mounjaro before you are scheduled to have surgery or other procedures. Common side effects The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn't go away. Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or Before using Mounjaro Your healthcare provider should show you how to use Mounjaro before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. If you take birth control pills by mouth, talk to your healthcare provider before you use Mounjaro. Birth control pills may not work as well while using Mounjaro. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Mounjaro and for 4 weeks after each increase in your dose of Mounjaro. Review these questions with your healthcare provider:❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?❑ Do you take other diabetes medicines, such as insulin or sulfonylureas?❑ Do you have a history of diabetic retinopathy?❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? It is not known if Mounjaro will harm your unborn baby or pass into your breast milk.❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements? How to take Read the Instructions for Use that come with Mounjaro. Use Mounjaro exactly as your healthcare provider says. Mounjaro is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Mounjaro 1 time each week, at any time of the day. Do not mix insulin and Mounjaro together in the same injection. You may give an injection of Mounjaro and insulin in the same body area (such as your stomach area), but not right next to each other. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Mounjaro, call your healthcare provider or seek medical advice promptly. Learn more Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to This summary provides basic information about Mounjaro but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you. TR CON CBS 05NOV2024Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram and LinkedIn. P-LLY Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements regarding the efficacy, safety and potential regulatory progress of Lilly's investigational medicines such as orforglipron as a potential treatment for adults with type 2 diabetes, insulin efsitora alfa as a potential treatment for adults with type 2 diabetes, retatrutide for potential use across multiple cardiometabolic indications, bimagrumab for potential use alone and in combination with other GLP-1 therapies in adults with overweight or obesity, eloralintide as a potential treatment for obesity and weight management, statements about the efficacy and safety of Zepbound (tirzepatide) as an approved treatment for adults with obesity or overweight, statements about the efficacy and safety of Mounjaro (tirzepatide) as an approved treatment for adults with type 2 diabetes, and reflects Lilly's current belief and expectations. However, as with any investigational and pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that studies will be initiated or completed as planned, that future study results will be consistent with the results to date, that investigational medicines will receive regulatory approval, or that approved medicines will achieve anticipated commercial success. Additionally, regulatory timelines and commercialization efforts may evolve based on emerging data, competitive dynamics, and regulatory interactions. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Refer to: Brooke Frost; 317-432-9145 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Business
- Yahoo
This Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic Boxes
In the cash grab for patients eager to get on GLP-1 weight loss drugs like Ozempic, startups are getting so sloppy that their marketing materials look like unintentional parody. Consider MEDVi, an online prescription hub for GLP-1s. The company wants you to know that it's "serious" about helping you lose weight, according to its website, which entreats visitors to join "50,000+ MEDVi patients" who have turned to the service for weight loss help. That help, it says, comes in the form of "personalized care" and "highly effective weight loss medications," which it characterizes later as "doctor-approved." At a subscription starting price of under $200 with "no insurance required," it adds, it's a "budget-friendly" semaglutide option. To drive its sales pitch home, MEDVi's website is packed with images of happy-looking, smiling people; the women in the smoothed-over pictures each wear sports bras in trendy colors, while the grinning men are decked out in T-shirts. There's also a slew of alleged customer success stories, which the company claims are from actual MEDVi patients. "Sometimes you have to see it to believe it," reads a blurb of copy, alongside a series of bef0re-and-after weight loss photos. "GLP-1 medication can be life-changing and improves mood, sleep, energy and longevity. Photos, testimonials and results are from MEDVi patients." Except, we couldn't help but notice, none of these alleged patients are real. Each image in the smiling, sports-bra'd crowd appears to have been generated from scratch using AI — and the before-and-after photos, more insidiously, are eerily convincing deepfakes, seemingly generated by lifting existing images of real people from across the web and using AI to alter their faces. MEDVi's site represents layers of sophisticated trickery that, while previously much more difficult, have been made incredibly accessible through easy-to-use text and image generators and deepfake tools. As profiteers race to flood the web with disorienting AI-powered content, including around buzzy products like GLP-1 meds, the eternal advice to not believe everything you read — and now, everything you see — online is now more urgent than ever. We first came across MEDVi in a deeply mangled digital advertisement found at the foot of a local news article showcasing a clearly AI-generated image of a box of Ozempic. To say nothing of the fact that the image used looks absolutely nothing like a real box of Ozempic, the AI-drawn box is covered with AI artifacts like twisted, gibberish letters, and includes a legume-like logo bearing no resemblance to the real logo used by Ozempic maker Novo Nordisk, which features an Apis bull. "Solution fo [sic] injection," reads one prominent piece of text on the ersatz box, while another claims that the package contains a "solutån [sic] for injection in pre-filled pen." "O)zenpic," reads a garbled and incorrectly-spelled Ozempic logo on the side of the box. Intrigued by the blatancy of the ad's AI slop even in the heavily scrutinized world of pharmaceuticals, we decided to explore further. Upon clicking the link, we were greeted by the website's first round of AI-generated people — who, though almost convincing, bear signs of AI-generation, like oddly-smooth curls and ears that blend mysteriously into the side of their head. Just underneath these images, MEDVi includes a rotating list of logos belonging to websites and news publishers, ranging from health hubs like Healthline to reputable publications like The New York Times, Bloomberg, and Forbes, among others — suggesting that MEDVi is reputable enough to have been covered by mainstream publications. Forbes, we found, did include MEDVi in a roundup of "Best Weight Loss Injections Of 2025," where it earned a "very good" rating of "9.4." The article appeared in Forbes Health, and includes a disclaimer noting that the page's content was "created independently from the Forbes Health Editorial team." But otherwise, there was no sign of MEDVi coverage in the New York Times, Bloomberg, or the other outlets it mentioned. The only other remotely mainstream news coverage we could find of the company was in an US Weekly article from earlier this month, titled "6 Affordable GLP-1 Solutions After the FDA Bans Generic Medications" that also circulated on Yahoo. (Both the Forbes Health and US Weekly articles were affiliate content, meaning they were created outside of normal editorial channels, and the outlets earn money when readers click the links on the page.) Perhaps nothing about MEDVi's site, though, is as egregious as its alleged patient before-and-after images. Under text telling possible customers that the "results speak for themselves," MEDVi features side-by-side pictures of three purported patients: "Sandra K," "Michael P," and "Melissa C." Contrasted with the stock photo-esque images featured elsewhere on the page, these images looked much less uncanny. Their bodies had more distinct, lifelike details, and objects and lettering seen in the background looked genuine. And when we dug through web searches to see if the images existed elsewhere, we realized that's because the photos of dramatic weight loss were indeed real. At least, from the neck down. What appears to have happened is that the sloperators behind MEDVi took images that had already been floating around the web for years, and used AI-powered deepfake tech to convincingly alter their faces. Take the side-by-side images of "Michael P," who MEDVi claims lost 48 pounds over just five months. We were able to find the original image in a Daily Mail article from 2018 — before semaglutide was even approved for weight loss purposes — that featured before-and-after photos of people who quit drinking, which was itself based on an undated Bored Panda article of "Before & After Pics That Show What Happens When You Stop Drinking." Per Bored Panda and the Daily Mail, the man in the original picture is a Redditor who posts fitness and sobriety content under the username u/iDoneDo. The Daily Mail article timestamps the Redditor's weight loss journey as occurring between 2016 and 2017, which we confirmed by finding u/iDoneDo's original Reddit post. That ages the image to long before the GLP-1 craze kicked off — and before AI started to fill the web with synthetic and deepfaked content. Web searches for the other alleged patients yielded similar results: inspirational weight-loss imagery that's drifted around the web for years, and altered to disguise the actual people in the images as fake MEDVi customers. To bolster its feigned legitimacy, MEDVi's site flaunts a lineup of doctors — full names and headshots included — that the startup claims to have partnered with. "MEDVi physicians are here to guide you every step of the way," reads the webpage, "bringing both their expertise and genuine care to keep you supported. When we searched for their names and images of these doctors, we discovered that they were, in fact, real medical professionals with LinkedIn pages, personal websites, and clear work histories. But to our surprise, these searches also returned yet another sketchy website for GLP-1 drugs. This one is called NuHuman, and offers a similar service, though it seems to be targeted specifically at the Chicago area. NuHuman's website is also crawling with AI slop, though once again features the same lineup of very real doctors. We contacted each doctor to ask if they could confirm their involvement with MEDVi and NuHuman. We heard back from one of those medical professionals at the time of publishing, an osteopathic medicine practitioner named Tzvi Doron, who insisted that he had nothing to do with either company and "[needs] to have them remove me from their sites." We also reached out to MEDVi, which didn't respond. When we tried to reach out to NuHuman with the site's listed email, the message bounced back. We did find some Reddit comments, though, warning other netizens to steer clear of MEDVi, claiming serious allegations of possible HIPPA violations, shady billing practices, and even damaged vials of seemingly bogus drugs causing physical harm. AI is making the web weirder and muddier than ever. And though MEDVi promises that "sometimes you have to see it to believe it," in our burgeoning AI-powered web, that's no longer the case. More on AI slop: Slop Farmer Boasts About How He Uses AI to Flood Social Media With Garbage to Trick Older Women
